NCT07205731 - Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2029

Study Completion Date

October 31, 2030

Conditions

Esophageal Squamous Cell Carcinoma (ESCC)

Interventions

DRUG

Tislelizumab is a fully humanized monoclonal antibody specific for human PD-1

It is the first study which evaluate efficacy and safety of anti PD-1 immune checkpoint inhibitor alone in the first-line treatment of elderly esophageal squamous-cell carcinoma patients who no fit to received chemotherapy with platine

Trial Locations (10)

51726

Centre Régional du Lutte Contre Le Cancer - Institut Godinot, Reims

64100

Centre Hospitalier de la Côte Basque, Bayonne

74370

Centre Hospitalier Annecy Genevois, Annecy

Unknown

CHU Clermont-Ferrand, Clermont-Ferrand

CHU Dijon, Dijon

Groupe Hospitalier Mutualiste, Grenoble

CHU Limoges, Limoges

Centre hospitalier de Perpignan, Perpignan

ICAN Strasbourg, Strasbourg

CHRU Tours, Tours

All Listed Sponsors

collaborator

BeiGene USA, Inc.

INDUSTRY

collaborator

Federation Francophone de Cancerologie Digestive

OTHER

lead

University Hospital, Clermont-Ferrand

OTHER